MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB)[1][2].
MOMIPP can induce intense macropinocytosis, leading to methuosis in cultured glioblastoma cells at low micromolar concentrations[1].
In U373 and Hs683 cell lines, 3 µM for MOMIPP induces cell vacuolization[1].
MOMIPP (10 μM) causes early disruptions of glucose uptake and glycolytic metabolism. MOMIPP selectively activates the JNK1/2 stress kinase pathway, resulting in phosphorylation of c-Jun, Bcl-2 and Bcl-xL[2].
Western Blot Analysis[2]
| Cell Line: | U251 cells |
| Concentration: | 10 μM |
| Incubation Time: | 4 h or 24 h |
| Result: | Activated the JNK stress kinase pathway. |
MOMIPP (80 mg/kg; i.p.; once daily; for 15 consecutive days) shows moderately effective in suppressing progression of intracerebral glioblastoma xenografts[2].
| Animal Model: | Athymic CrTac:NCR-Foxn1 |
| Dosage: | 80 mg/kg |
| Administration: | i.p.; once daily; for 15 consecutive days |
| Result: | Suppressed progression of intracerebral glioblastoma xenografts. |